Clinical trial · Interventional
Comparative Study of Diagnostic and Prognosis Biomarkers of Prostate Cancer in Liquid Biopsy (HOPE)
Comparative Study of Diagnostic and Prognosis Biomarkers of Prostate Cancer in Liquid Biopsy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Constitution of a biological collection within the framework of the establishment of a diagnostic, prognostic and active surveillance test for prostate cancer from long non-coding RNA biomarkers, in 3 cohorts of patients, with cancer of the prostate, with suspected cancer without biopsy confirmation or with prostatic hyperplasia and healthy donors. This biological collection will also be used as a support for further researches on the identification of biomarkers and genetic markers to improve the prognosis and diagnostic management of patients with prostate pathologies.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Healthy Donors | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Urine sampling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- OTHER
- label
- Patients with prostate cancer
- description
- Patients with suspected prostate cancer (MRI or digital rectal examination), or prostatic hyperplasia with a PSA level\> 4 ng / ml
- interventionNames
- Other: Urine sampling
- type
- OTHER
- label
- Patients with suspected cancer without confirmation on biopsy, or with hyperplasia of the prostate
- description
- Patients with suspected prostate cancer (MRI or digital rectal examination), or prostatic hyperplasia with a PSA level\> 4 ng / ml
- interventionNames
- Other: Urine sampling
- type
- OTHER
- label
- Healthy donors
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: Concerning patients: 1. / Patient with suspected prostate cancer or prostatic hyperplasia with a PSA level ≥ 4 ng / ml 2. / Patient diagnosed by prostate MRI in the course of treatment 3. / No infectious episode in the week before the visit (in particular no urinary tract infection) documented by dipstick and absence of fever 4. / Information of the patient and signature of informed consent or his legal representative. 5. / Participant affiliated to a social security scheme Regarding healthy volunteers: 1. / Male from 50 to 70 years old 2. / PSA level \< 4 ng / mL 3. / No infectious episode in the week before the visit (in particular no urinary tract infection), documented by dipstick and the absence of fever 4. / Absence of cancer and history of haematological pathologies \< 5 years (in particular leukemia, lymphoma). 5. / Patient information and signature of consent Exclusion Criteria: 1 / Participants who refused to participate in the biological collection 2) Persons deprived of their liberty or under guardianship. 3) Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.
References
Publications (0)
Data not yet available